{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:46:58Z","timestamp":1785851218118,"version":"3.56.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Hospital Pharmacy Research Grant from Jiangsu Provincial Pharmaceutical Association - Aosaikang","award":["A202534"],"award-info":[{"award-number":["A202534"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Isavuconazole is approved for invasive aspergillosis (IA) and mucormycosis, but real-world data in patients with hematological malignancies are limited. This retrospective study (2022\u20132025) included adult patients with hematological malignancies and proven\/probable invasive mold disease (IMD) who were treated with isavuconazole for \u226572 h at two Chinese hospitals. The primary endpoint was week 6 treatment success (survival, clinical\/radiological improvement, and no discontinuation due to failure\/toxicity). Secondary endpoints included all-cause and IMD-attributable mortality at weeks 6 and 12 (competing risk analysis). Among 84 patients, 62 had aspergillosis (69.4% treatment success), 14 had mucormycosis (35.7%), and 8 had mixed infection (25.0%); the overall week 6 treatment success was 59.5% (50\/84), with significant variation across infection types (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007) and treatment strategy (monotherapy 65.6% vs. combination 43.5%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), but not by therapy role. Week 6 all-cause and IMD-attributable mortality rates were 17.9% and 11.9%, respectively; IMD-attributable mortality rate was lower with monotherapy (6.6%) than with combination therapy (26.1%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.023). Week 12 all-cause mortality rate was 21.6%. Competing risk analysis showed significant differences in week 12 attributable mortality by infection type (overall\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04): aspergillosis, 9.7%; mucormycosis, 36.0%; and mixed, 13.0%. Monotherapy was associated with lower attributable mortality than combination therapy (8.2% vs. 31.0%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01). Four patients (4.8%) had drug-related adverse events (one discontinuation due to vomiting). In this real-world Chinese cohort, isavuconazole achieved 59.5% treatment success with favorable safety. Infection type and treatment strategy were key prognostic factors: aspergillosis and monotherapy were associated with better outcomes, whereas mucormycosis and combination therapy were associated with higher attributable mortality risk.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00543-26","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:57:48Z","timestamp":1783349868000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks"],"prefix":"10.1128","volume":"70","author":[{"given":"Jirui","family":"Zhang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05kvm7n82","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, The Fifth People\u2019s Hospital of Suzhou\/The Affiliated Infectious Diseases Hospital, Suzhou Medical College of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Xu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04n3e7v86","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Mao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04n3e7v86","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04n3e7v86","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1131-7041","authenticated-orcid":true,"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04n3e7v86","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.058255"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-025-00794-8"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.805514"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00102-6"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13082"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152900"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30312-3"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/517849"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/595846"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.3.322"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767110-00004"},{"key":"e_1_3_4_14_2","unstructured":"US Food and Drug Administration. 2023. Cresemba (Isavuconazonium sulfate) prescribing information. Available from: https:\/\/www.astellas.us\/docs\/cresemba.pdf. Retrieved 1 Jul 2024."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2018.02.002"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac114"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-025-02674-x"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S505709"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof11060456"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof11090648"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1751"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00138-22"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10633-7"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13122677"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202410-2045ST"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.03.029"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004312"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2412565"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10439-y"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae139"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00543-26","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00543-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:03:06Z","timestamp":1785848586000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00543-26"}},"subtitle":[],"editor":[{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,5]]}},"alternative-id":["10.1128\/aac.00543-26"],"URL":"https:\/\/doi.org\/10.1128\/aac.00543-26","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"2026-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00543-26"}}